FENC
Fennec Pharmaceuticals Inc
North American company
Healthcare
Biotechnology
/
Bid
-
Ask
-
Last Traded
-
Chg
-
-
XNAS
-
Updated: -
Research
News & analysis
Times are shown in GMT-4, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
This stock can be held in:
/
Company Profile
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities.
NASDAQ:FENC
CA31447P1009
USD
Loading Comparison
Latest FENC News